Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675075 · ClinicalTrials.gov registry record
DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 34
- Enrollment target
NCT02675075: Completed study, sponsored by VA Office of Research and Development.
NCT02675075 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02675075 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
A disease called Amyotrophic lateral sclerosis (or ALS), which leads to difficulty swallowing, breathing, and movement, has been found to be higher for those serving in the military than in the general population. There are approximately 4,200 Veterans with ALS and roughly 1,000 new cases each year. When doctors attempt to determine the degree to which an ALS patient is suffering from the disease, they apply tests that are "graded" by experts. However, this approach to testing patients may not be very accurate. Researchers aim to use a system called DESIPHER to "listen" to ALS patients and find speech mistakes related to their condition. Researchers believe that, by detecting different types of errors, DESIPHER serves as a new kind of indicator of medical problems such as difficulty breathing or swallowing, without human "grading". This may also lead to a better system for automatically understanding ALS patients' speech.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2017-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675075
The ClinicalTrials.gov registry entry for NCT02675075 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02675075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02675075 about?
NCT02675075 is a clinical study titled "DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS". A disease called Amyotrophic lateral sclerosis (or ALS), which leads to difficulty swallowing, breathing, and movement, has been found to be higher for those serving in the military than in the general population. There are approximately 4,200 Veterans with ALS and roughly 1,000 new cases each year....
What is the current status of trial NCT02675075?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2016-01-01. Estimated completion is 2017-12-31.
Who is sponsoring clinical trial NCT02675075?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.